Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease.

Tytuł:
The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease.
Autorzy:
Phrueksotsai S; Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Pinyopornpanish K; Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Euathrongchit J; Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Leerapun A; Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Phrommintikul A; Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Buranapin S; Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Chattipakorn N; Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.; Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.; Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, Thailand.
Thongsawat S; Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Źródło:
Journal of gastroenterology and hepatology [J Gastroenterol Hepatol] 2021 Oct; Vol. 36 (10), pp. 2952-2959. Date of Electronic Publication: 2021 Jun 23.
Typ publikacji:
Journal Article; Randomized Controlled Trial
Język:
English
Imprint Name(s):
Original Publication: Melbourne ; Boston : Blackwell Scientific Publications, c1986-
MeSH Terms:
Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/drug therapy
Non-alcoholic Fatty Liver Disease*/diagnostic imaging
Non-alcoholic Fatty Liver Disease*/drug therapy
Benzhydryl Compounds ; Blood Glucose ; Body Weight ; Double-Blind Method ; Glucosides ; Glycated Hemoglobin/analysis ; Humans ; Hypoglycemic Agents ; Intra-Abdominal Fat/diagnostic imaging
References:
Fuchs M. New medical treatment strategies for nonalcoholic steatohepatitis. Curr. Treat. Opt. Gastroenterol. 2015; 13: 259-273.
Mudaliar S, Polidori D, Zambrowicz B, Henry RR. Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care 2015; 38: 2344-2353.
Qiang S, Nakatsu Y, Seno Y et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol. Metab. Syndr. 2015; 7: 104.
Yokono M, Takasu T, Hayashizaki Y et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur. J. Pharmacol. 2014; 727: 66-74.
ElMahdy MK, Helal MG, Ebrahim TM. Potential anti-inflammatory effect of dapagliflozin in HCHF diet-induced fatty liver degeneration through inhibition of TNF-α, IL-1β, and IL-18 in rat liver. Int. Immunopharmacol. 2020; 86: 106730.
Swe MT, Thongnak L, Jaikumkao K, Pongchaidecha A, Chatsudthipong V, Lungkaphin A. Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats. Clin. Sci. (Lond.) 2019; 133: 2415-2430.
Tang L, Wu Y, Tian M et al. Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 2017; 313: E563-E576.
McGurnaghan SJ, Brierley L, Caparrotta TM et al. The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study. Diabetologia 2019; 62: 621-632.
Bolinder J, Ljunggren O, Kullberg J et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J. Clin. Endocrinol. Metab. 2012; 97: 1020-1031.
Aso Y, Kato K, Sakurai S et al. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease. Int. J. Clin. Pract. 2019; 73: e13335.
Kurinami N, Sugiyama S, Yoshida A et al. Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 2018; 142: 254-263.
Cho KY, Nakamura A, Omori K et al. Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. J Diabetes Investig. 2020.
Eriksson JW, Lundkvist P, Jansson PA et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia 2018; 61: 1923-1934.
Phrommintikul A, Wongcharoen W, Kumfu S et al. Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study. Br. J. Clin. Pharmacol. 2019; 85: 1337-1347.
Jehangir M, Nazir R, Jang A, Rana A, Rafique S, Dar FS. Macrovesicular steatosis in living related liver donors: correlation of biopsy findings with CT liver attenuation index and body mass index. Clin. Transplant. 2016; 30: 1016-1020.
Park SH, Kim PN, Kim KW et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology 2006; 239: 105-112.
Lee YH, Kim JH, Kim SR et al. Lobeglitazone, a novel thiazolidinedione, improves non-alcoholic fatty liver disease in type 2 diabetes: its efficacy and predictive factors related to responsiveness. J. Korean Med. Sci. 2017; 32: 60-69.
Koutoukidis DA, Astbury NM, Tudor KE et al. Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and meta-analysis. JAMA Intern. Med. 2019.
Choi DH, Jung CH, Mok JO, Kim CH, Kang SK, Kim BY. Effect of dapagliflozin on alanine aminotransferase improvement in type 2 diabetes mellitus with non-alcoholic fatty liver disease. Endocrinol Metab (Seoul). 2018; 33: 387-394.
Shimizu M, Suzuki K, Kato K et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes. Metab. 2019; 21: 285-292.
Tobita H, Sato S, Miyake T, Ishihara S, Kinoshita Y. Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study. Curr. Ther. Res. Clin. Exp. 2017; 87: 13-19.
Takase T, Nakamura A, Miyoshi H, Yamamoto C, Atsumi T. Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects. Endocr. J. 2017; 64: 363-367.
Kern M, Kloting N, Mark M, Mayoux E, Klein T, Bluher M. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. Metabolism 2016; 65: 114-123.
Merovci A, Solis-Herrera C, Daniele G et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J. Clin. Invest. 2014; 124: 509-514.
Cao H. Adipocytokines in obesity and metabolic disease. J. Endocrinol. 2014; 220: T47-T59.
Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism 2016; 65: 1062-1079.
Wu P, Wen W, Li J et al. Systematic review and meta-analysis of randomized controlled trials on the effect of SGLT2 inhibitor on blood leptin and adiponectin level in patients with type 2 diabetes. Horm. Metab. Res. 2019; 51: 487-494.
Bailey CJ, Iqbal N, T'Joen C, List JF. Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes. Metab. 2012; 14: 951-959.
Liao X, Wang X, Li H et al. Sodium-glucose cotransporter 2 (SGLT2) inhibitor increases circulating zinc-A2-glycoprotein levels in patients with type 2 diabetes. Sci. Rep. 2016; 6: 32887.
Fadini GP, Bonora BM, Zatti G et al. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. Cardiovasc. Diabetol. 2017; 16: 42.
Grant Information:
070/2560 (ST) Faculty of Medicine Research Fund, Chiang Mai University, Thailand; National Science and Technology Development Agency Thailand (NSTDA Research Chair Grant); Chiang Mai University Funding (Center of Excellence Award) (NC)
Contributed Indexing:
Keywords: diabetes mellitus, type 2; fatty liver; hypoglycemic agents; non-alcoholic fatty liver disease; sodium-glucose transporter 2 inhibitors
Substance Nomenclature:
0 (Benzhydryl Compounds)
0 (Blood Glucose)
0 (Glucosides)
0 (Glycated Hemoglobin A)
0 (Hypoglycemic Agents)
1ULL0QJ8UC (dapagliflozin)
Entry Date(s):
Date Created: 20210615 Date Completed: 20220105 Latest Revision: 20221207
Update Code:
20240104
DOI:
10.1111/jgh.15580
PMID:
34129252
Czasopismo naukowe
Background and Aim: Sodium-glucose cotransporter 2 inhibitors have shown excellent results in glucose control in type 2 diabetes mellitus (T2DM) patients, while also promoting weight loss. These mechanisms may be beneficial in the treatment of non-alcoholic fatty liver disease (NAFLD). Our study aims to investigate the effect of dapagliflozin on hepatic and visceral fat contents and related biochemical markers in T2DM with NAFLD patients.
Methods: This is a double-blinded placebo-controlled randomized, single-center study. Non-insulin-dependent T2DM patients with NAFLD were prospectively enrolled and randomly assigned to receive either dapagliflozin (10 mg/day) or placebo for 12 weeks. The primary end-point was the changes in intrahepatic lipid contents, evaluated by the liver attenuation index.
Results: Of 40 patients enrolled, 38 patients completed the study (dapagliflozin group, n = 18; placebo group, n = 20). Baseline demographic and laboratory findings were similar in both groups. After 12 weeks of treatment, dapagliflozin significantly decreased intrahepatic lipid contents demonstrated by an increase in liver attenuation index in comparison with the placebo treatment (5.8 ± 5.1 vs 0.5 ± 6.1 Hounsfield units, P = 0.006). Significant reduction in bodyweight, bodyfat, visceral fat/subcutaneous fat ratio, hemoglobin A1c, and alanine aminotransferase were also observed in the dapagliflozin-treated group as compared with the placebo group (all P < 0.05). There was no significant difference in adipokines including adiponectin, leptin, and tumor necrosis factor-α changes between the dapagliflozin-treated group and the placebo group (all P = nonsignificant).
Conclusion: Dapagliflozin treatment for 12 weeks is associated with improvement in hepatic fat content, a decrease in visceral fat and bodyweight, enhanced glycemic control, and improved liver biochemistry among T2DM patients with NAFLD.
(© 2021 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies